FDA Setback News: Recent discussions on social media about Aquestive Therapeutics have centered on a significant regulatory hurdle. The FDA has flagged deficiencies in the company's New Drug Application for Anaphylm, an oral allergy treatment, causing a sharp decline in stock price. This news has sparked intense reactions among investors.
Investor Reactions: Many on social media express concern over the potential delay in approval, with some fearing it could impact the company's near-term prospects. Others remain hopeful, pointing to the ongoing review process and the company's strong cash position as reasons for optimism. The dialogue reflects a mix of frustration and cautious patience.
Market Impact: Posts highlight a notable drop in AQST's stock value following the announcement, with some users debating the long-term implications. A few argue the dip presents a buying opportunity, while others urge caution until more clarity emerges. The conversation remains dynamic as the January 31 PDUFA date approaches.
Note: This discussion summary was generated from an AI condensation of post data.
Aquestive Therapeutics Insider Trading Activity
Aquestive Therapeutics insiders have traded $AQST stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $AQST stock by insiders over the last 6 months:
- CASSIE JUNG (Chief Operating Officer) has made 0 purchases and 2 sales selling 129,755 shares for an estimated $784,600.
- DANIEL BARBER (President and CEO) has made 0 purchases and 2 sales selling 91,743 shares for an estimated $553,591.
- PETER E. BOYD (See Remarks) has made 0 purchases and 3 sales selling 35,000 shares for an estimated $212,500.
- CARL N KRAUS (Chief Medical Officer) sold 20,272 shares for an estimated $141,904
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Aquestive Therapeutics Revenue
Aquestive Therapeutics had revenues of $12.8M in Q3 2025. This is a decrease of -5.43% from the same period in the prior year.
You can track AQST financials on Quiver Quantitative's AQST stock page.
Aquestive Therapeutics Hedge Fund Activity
We have seen 101 institutional investors add shares of Aquestive Therapeutics stock to their portfolio, and 43 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 2,625,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,673,750
- SAMSARA BIOCAPITAL, LLC added 2,500,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,975,000
- MILLENNIUM MANAGEMENT LLC removed 1,690,511 shares (-56.7%) from their portfolio in Q3 2025, for an estimated $9,449,956
- PALE FIRE CAPITAL SE removed 1,583,319 shares (-94.4%) from their portfolio in Q3 2025, for an estimated $8,850,753
- PERCEPTIVE ADVISORS LLC added 1,569,679 shares (+71.7%) to their portfolio in Q3 2025, for an estimated $8,774,505
- VANGUARD GROUP INC added 1,333,627 shares (+30.8%) to their portfolio in Q3 2025, for an estimated $7,454,974
- COMMONWEALTH EQUITY SERVICES, LLC added 1,058,725 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,918,272
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Aquestive Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $AQST in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/07/2025
- JMP Securities issued a "Market Outperform" rating on 10/09/2025
- Oppenheimer issued a "Outperform" rating on 09/08/2025
To track analyst ratings and price targets for Aquestive Therapeutics, check out Quiver Quantitative's $AQST forecast page.
Aquestive Therapeutics Price Targets
Multiple analysts have issued price targets for $AQST recently. We have seen 3 analysts offer price targets for $AQST in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- David Amsellem from Piper Sandler set a target price of $8.0 on 11/07/2025
- Jason Butler from JMP Securities set a target price of $12.0 on 10/09/2025
- Francois Brisebois from Oppenheimer set a target price of $8.0 on 09/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
